最新消息‎ > ‎

Dabigatran v.s Warfarin in the prevention of stroke, systemic embolism and Major bleeding rate

張貼者:2011年3月11日 下午2:32Dr. Chu
3/11 在漢神巨蛋聽了北榮江晨恩教授演講新一代口服抗凝血劑 Dabigatran 的分析:
整理如下
1.  Direct thrombin (factor IIa) inhibitor
2. 在 CHADS2 or CHA2DS2-VASc Score 大於或等於 2分的af患者, 不管是 Paroxysmal or permanent af, 給予OAC可以降低Stroke機率
3. Bleeding Risk 可用 HAS BLED Score來評估, 大於或等於 3分風險較高
4. The time in therapeutic range (TTR) 在 af 要控制在 65%以上,能減少STOKE
5. Dabagatran: according to Rely Study
   110 mg bid use,   superior to warfarin in Major bleeding rate, RRR 20%, p=0.003,
                               Prevention of hemorrhagic stroke, RRR 69%,  p<0.001
                               and Intracranial bleeding, RRR 69%,  p<0.001
                          
   150 mg bid use,   superior to warfarin in the prevention of stroke and systemic embolism, RRR 34%, p<0.001  ,
                                vascular mortality, RRR 15%,  p=0.04
                                Prevention of hemorrhagic stroke, RRR 74%,  p<0.001
                                and Intracranial bleeding, RRR 69%,  p<0.001
Comments